Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.44 |
| ▸ | MAOA | P21397 | 5/20 | 0.44 |
| ▸ | KDM1A | O60341 | 4/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | YAP1 | P46937 | 3/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL840905 | 1.00 | MAOB (0.44) | MAOBMAOAKDM1AKCNH2HTR2C | |
| SCHEMBL311161 | 1.00 | MAOB (0.44) | MAOBMAOAKDM1AKCNH2HTR2C | |
| SCHEMBL2840466 | 0.89 | KCNH2 (0.46) | MAOBKDM1AKCNH2YAP1NR4A2 | |
| SCHEMBL14343907 | 0.86 | KDM1A (0.41) | MAOBKDM1A | |
| SCHEMBL841064 | 0.81 | KCNH2 (0.52) | MAOBMAOAKDM1AKCNH2HTR2C | |
| SCHEMBL310182 | 0.81 | KCNH2 (0.52) | MAOBMAOAKDM1AKCNH2HTR2C | |
| SCHEMBL840024 | 0.81 | KCNH2 (0.52) | MAOBMAOAKDM1AKCNH2HTR2C | |
| SCHEMBL6744373 | 0.79 | KLK7 (0.42) | — | |
| SCHEMBL6959509 | 0.72 | NPC1 (0.44) | MAOBMAOAKDM1AKCNH2YAP1 | |
| SCHEMBL4062398 | 0.71 | MAOB (0.56) | MAOBLTA4HNR4A1NR4A2NR4A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153681-B2 | Method of treating epilepsy by administering 5-(4{[(2-fluorophenyl)methyl]oxy}phenyl)prolinamide | Convergence Pharmaceuticals Limited (GB) | 2012-04-10 | — | — | US | disclosed |
| US-8143306-B2 | Methods of treating bipolar disorders | Convergence Pharmaceuticals Limited (GB) | 2012-03-27 | — | — | US | disclosed |
| US-20110098335-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2011-04-28 | — | — | US | disclosed |
| US-7855218-B2 | (5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide; depression or a mood disorder ; modulation of use-dependent voltage-gated sodium channels | Convergence Pharmaceuticals Limited (GB) | 2010-12-21 | — | — | US | disclosed |
| US-20100105754-A1 | 5-(4PHENYL)PROLINAMIDE FOR TREATMENT OF EPILEPSY | GLAXO GROUP LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
| US-7655693-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2010-02-02 | — | — | US | disclosed |
| US-20080306122-A1 | Novel Compounds | Convergence Pharmaceuticals Limited (GB) | 2008-12-11 | — | — | US | disclosed |
| US-20080280969-A1 | Novel Compounds | GLAXO GROUP LIMITED | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098335-A1 | NOVEL COMPOUNDS | SCN1A, SCN1B, SCNN1B | MAOB 1571/4885MAOA 2022/4885KDM1A 2359/4885 |
| US-20080306122-A1 | Novel Compounds | CYP11B1, CYP11B2, CYP46A1 | MAOB 1619/4885MAOA 3055/4885KDM1A 3826/4885 |
| US-20080280969-A1 | Novel Compounds | CYP11B2, CYP46A1, SLC10A1 | MAOB 1719/4885MAOA 2630/4885KDM1A 3354/4885 |
| US-20100105754-A1 | 5-(4PHENYL)PROLINAMIDE FOR TREATMENT OF EPILEPSY | SCN5A, SCN1A, SCN7A | MAOB 1767/4885MAOA 2098/4885KDM1A 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.